Bryant

BrYet is a clinical-stage biotechnology company based in Houston, Texas, dedicated to developing curative therapies for metastatic cancers, particularly those affecting the liver and lungs. The company utilizes a proprietary drug delivery platform based on nanoporous silicon microparticles (iNPG) to overcome biological transport barriers and deliver multi-component therapeutics directly to tumor sites. BrYet's lead oncology candidate, ML-016, has demonstrated significant efficacy in preclinical models and is advancing into clinical trials following a recent Investigational New Drug (IND) application. By targeting specific transport phenotypes, the company aims to transform the treatment landscape for otherwise incurable advanced stage cancers.